Yahoo
NasdaqCM - Delayed Quote USD

Viking Therapeutics, Inc. (VKTX)

34.87 +0.89 (+2.62%)
At close: September 4 at 4:00:00 PM EDT
34.86 -0.01 (-0.03%)
After hours: September 4 at 7:59:20 PM EDT
Trade VKTX on Coinbase
Chart Range Bar
Loading chart for VKTX

What's happening with VKTX?

40m ago
Powered by Yahoo Scout

Viking Therapeutics (VKTX) has experienced significant market optimism, with a 411% returnover five years driven by its lead candidate VK2735. However, analysts express concerns about its high valuation and upcoming trial results that will be crucial for justifying current prices.

Powered by Yahoo Scout
  • Previous Close 33.98
  • Open 33.75
  • Bid 32.55 x 100
  • Ask 35.70 x 100
  • Day's Range 33.56 - 34.95
  • 52 Week Range 22.96 - 43.15
  • Volume 1,398,226
  • Avg. Volume 2,249,658
  • Market Cap (intraday) 4.068B
  • Beta (5Y Monthly) 0.68
  • PE Ratio (TTM) --
  • EPS (TTM) -4.67
  • Earnings Date (est.) Oct 28, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 92.39

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

www.vikingtherapeutics.com

65

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

VKTX
0.88%
S&P 500 (^GSPC)
12.75%

1-Year Return

VKTX
31.44%
S&P 500 (^GSPC)
18.71%

3-Year Return

VKTX
140.32%
S&P 500 (^GSPC)
70.93%

5-Year Return

VKTX
412.79%
S&P 500 (^GSPC)
70.18%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue --
Earnings -128.02M
Profit Margin 0.00%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-150M
-100M
-50M
0
0.0%

Analyst Insights

View More

Top Analyst

BTIG
60/100
Latest Rating
Buy

Analyst Price Targets

35.00
92.39 Average
34.87 Current
125.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/11/2026
Analyst JP Morgan
Rating Action Maintains
Rating Overweight
Price Action Lowers
Price Target 75 -> 65

Statistics

View More

Valuation Measures

Annual
As of 9/1/2026
  • Market Cap

    3.93B

  • Enterprise Value

    3.43B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    9.62

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -51.86%

  • Return on Equity (ttm)

    -88.85%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -534.8M

  • Diluted EPS (ttm)

    -4.67

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    501.66M

  • Total Debt/Equity (mrq)

    1.00%

  • Levered Free Cash Flow (ttm)

    -230.79M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

34.87 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

Research Reports

View More
  • Daily – Vickers Top Buyers & Sellers for 07/30/2026

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

  • Daily – Vickers Top Buyers & Sellers for 01/06/2026

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

  • Daily – Vickers Top Buyers & Sellers for 10/29/2025

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

  • Daily – Vickers Top Buyers & Sellers for 07/07/2025

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: